Atypical Cases of Posterior Reversible Encephalopathy Syndrome

564 References 1 Yusuf S, Teo KK, Pogue J, et al; for the ONTARGET investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–1559. 2 Graves SW, Moore TJ, Seely EW: Increased platelet angiotensin II receptor number in pregnancy-induced hypertension. Hypertension 1992; 20: 627–632. 3 Serebruany VL, Malinin AI, Lowry DR, Sane DC, Webb RL, Gottlieb SO, Hennekens CH: Platelet inhibition by valsartan and valeryl 4-hydroxy valsartan: a possible missing link to explain benefits of angiotensin II receptor blockers in patients after acute vascular events. J Cardiovasc Pharmacol 2004; 43: 677–684. 4 Serebruany VL, Pokov A, Malinin AI, J-F Tanguay, Bhatt DL, Sane DC, Hennekens CH: Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) Trial. Am Heart J 2006; 151: 92–99. 5 Diener HC, Sacco R, Yusuf S; Steering Committee; PRoFESS Study Group: Rationale, design and baseline data of a randomized, doubleblind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007; 23: 368–380.